Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193245 · ClinicalTrials.gov registry record · Phase 2
Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00193245: Completed Phase 2 study, sponsored by SCRI Development Innovations.
NCT00193245 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 80 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00193245, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
In this trial we will evaluate and compare the efficacy and toxicity of oral topotecan with intravenous docetaxel in the second-line treatment of patients with non-small cell lung cancer.
Interventions
- DRUG Docetaxel
- DRUG Topotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2000-11 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
What the finished NCT00193245 record still lists
NCT00193245 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00193245 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00193245 about?
NCT00193245 is a clinical study titled "Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer". In this trial we will evaluate and compare the efficacy and toxicity of oral topotecan with intravenous docetaxel in the second-line treatment of patients with non-small cell lung cancer.
What is the current status of trial NCT00193245?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2000-11. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00193245?
The interventions under investigation include: Docetaxel (DRUG), Topotecan (DRUG).
Who is sponsoring clinical trial NCT00193245?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00193245's enrollment target sits among peer trials
80 842nd of 2000 higher than 1,117 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia